Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study
Neto F, Hitchings M, Amin A, de França G, Lind M, Torres M, Tsuha D, de Oliveira R, Cummings D, Dean N, Andrews J, Ko A, Croda J, Ranzani O. Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study. The Lancet Regional Health - Americas 2024, 34: 100755. PMID: 38737773, PMCID: PMC11087726, DOI: 10.1016/j.lana.2024.100755.Peer-Reviewed Original ResearchSevere COVID-19Cohort ACohort B.Cohort BTwo-doseMRNA vaccinesPrimary outcomeBooster dose effectivenessCOVID-19 outcomesPopulation-based cohort studyDose of COVID-19 vaccinePopulation-based cohortPopulation-based cohort of individualsCOVID-19 vaccine dosesSevere COVID-19 outcomesFollow-upCohort studyMRNA-basedVaccine doseCohort of individualsVaccine effectivenessVaccine combinationsDoseLower hazardCohortFactors influencing adverse events following COVID-19 vaccination
Villanueva P, McDonald E, Croda J, Croda M, Dalcolmo M, dos Santos G, Jardim B, Lacerda M, Lynn D, Marshall H, Oliveira R, Rocha J, Sawka A, Val F, Pittet L, Messina N, Curtis N. Factors influencing adverse events following COVID-19 vaccination. Human Vaccines & Immunotherapeutics 2024, 20: 2323853. PMID: 38445666, PMCID: PMC10936640, DOI: 10.1080/21645515.2024.2323853.Peer-Reviewed Original ResearchConceptsVaccine typesSystemic reactionsIncidence of AEFIAdverse eventsVaccine doseIncidence of adverse eventsCovid-19 specific vaccineCOVID-19 vaccineNested cohort studyIgG antibody responsesRisk of AEFICOVID-19 vaccine typesChAdOx1 recipientsBNT162b2 recipientsCohort studyPfizer-BioNTechCoronaVac vaccineAntibody responseChAdOx1Oxford-AstraZenecaCoronaVacBNT162b2Local reactionsDoseDevelopment of COVID-19 vaccines